Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics, will announce its financial results for the third quarter of 2024 on October 31, 2024, after the market closes. Following the announcement, the management team will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a corporate update.
The company's lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody currently under evaluation in multiple global clinical trials. It is being investigated as a potential treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) for zanidatamab has been accepted by the U.S. Food and Drug Administration (FDA) with Priority Review for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. A similar BLA has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China.
Advancing Pipeline and Strategic Partnerships
Zymeworks is also progressing a pipeline of wholly-owned product candidates, leveraging its expertise in antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways. Phase 1 studies are actively recruiting for ZW171 and ZW191 at sites worldwide. These programs aim to address areas of significant unmet medical need.
In addition to its internal pipeline, Zymeworks has established strategic partnerships with global biopharmaceutical companies to further leverage its therapeutic platforms. These collaborations support the development and commercialization of innovative antibody-based therapeutics.
About Zymeworks Inc.
Zymeworks is dedicated to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company's mission is to make a meaningful difference in the lives of people affected by difficult-to-treat cancers and other diseases. Zymeworks' therapeutic platforms and integrated drug development engine enable the precise engineering and development of highly differentiated antibody-based therapeutic candidates.
